GSK Consumer Healthcare Signed Joint Business Plan with Ali Health to Outline the Blueprint of Consumer Healthcare E-commerce
02 April 2019
April 2, 2019, Hangzhou——GlaxoSmithKline Consumer Healthcare (hereinafter referred to as "GSK Consumer Healthcare") and Alibaba Health Information Technology Limited, Alibaba’s flagship healthcare platform, signed a Joint Business Plan (JBP). The two parties will strengthen the cooperation in big data application, marketing model innovation and professional service offerings, to co-develop a ‘big heath” strategy in China. The two parties will explore in the field of consumer healthcare new retail and strive to reach Chinese consumers more deeply in order to provide Chinese consumers with a life of better health and higher quality.
Through this cooperation, GSK Consumer Healthcare and Ali Health will share resources and dedicate joint efforts to category construction, improvement of brand penetration and enhancement of consumer insights. They will provide more health products and solutions in the field of respiratory, pain relief, as well as services including online expert consultation and health education. Through these digital platforms, the two parties aim to raise the selfcare awareness among Chinese consumers and support the establishment of China’s “big Health” blueprint.
As early as in 2013, GSK Consumer Healthcare has begun to tap into digital marketing and e-commerce business. In 2016, GSK Consumer Healthcare started the collaboration with Alibaba to unlock a new model of consumer insight and brand communication with the empowerment of data. Marc Speichert, Chief Digital Officer of GSK Consumer Healthcare, said: "In recent years, digitalisation has brought rapid changes to the Chinese market. GSK Consumer Healthcare has been leading the industry to find new ways of connecting with consumers and empower them to monitor and manage their own health. By using the power of digital, data and analytics, we have been able to bring healthcare knowledge and provide professional advice to more people and add more value to our brands that are loved by consumers. The partnership with Ali Health will help us connect with even more consumers and continue to improve our service and product offerings. We believe by working together GSK and Ali Health will generate more new ideas in digital marketing and win more consumers."
Jane Xu, Area General Manager of Greater China of GSK Consumer Healthcare, said: “The Chinese market has been defined as the 'growth engine' for GSK Consumer Healthcare globally. In recent years, we have been committed to digital transformation and marketing innovation, which has become a new driving force for our business growth. With the partnership with Ali Health, we could communicate with consumers more rapidly, directly and accurately on the online platform. It also allows us to help Chinese consumers do more, feel better, and live longer."
Gary Wang, executive director of Ali Health and general manager of Alibaba’s Healthcare Group, said: “GSK Consumer Healthcare owns many well-known brands in China, and at the same time has strong expertise and rich resources in the pharmaceutical field. Ali Health will benefit from the collaboration with GSK Consumer Healthcare in product category construction. I am glad to have close cooperation with GSK Consumer Healthcare. I hope that we can not only promote sales and business growth, but also build an important base for brand innovation and consumer insight. Ali Health will work with GSK Consumer Healthcare in the fields of digital healthcare, online medical service and health management to provide consumers with better products and services."
About GSK Consumer Healthcare
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Our Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands. We build world-class brands that consumers trust and experts recommend for oral health, pain relief, respiratory, skin health, nutrition and digestive health.
In China, these brands include: Fenbid, Voltaren, Bactroban, Flixonase, Sensodyne, Polident, Contac, Lamisil, etc.
For more information, please visit /en-gb/about-us/.